ClinicalTrials.gg
Active, not recruitingNCT07053384ENTRANCEUpdated Sep 28, 2026

A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV

A Phase 1 interventional study of VH3810109 and Fostemsavir (FTR) in HIV Infections, sponsored by ViiV Healthcare. Active, not recruiting at 41 sites in 6 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

Updated Sep 28, 2026Enrollment updated4 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
107
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 266 studies in HIV Infections by GlaxoSmithKline — 15 open to participants now, 27 under way, 8 of them phase 3. HIV Infections · GlaxoSmithKline.

Enrollment
91st of 210
107 · median 82
Started
2025
with 3 others
Phase 1
83 of 266
9 open now
Primary completion
2027-01
later than 12 of 26 live
Registered
255th of 266
by date

Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 91st largest by enrollment of the 210 interventional ones that give a count, is one of 4 that started in 2025, is one of 83 in phase 1, reaches primary completion later than 12 of the 26 other live ones, and was the 255th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

15 of the 266 studies in HIV Infections by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in HIV Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

This study investigates the use of VH3810109 with or without FTR to reduce the size and activity of the HIV viral reservoir in two sub-populations of people living with HIV: treatment-naïve adults (Population 1) and treatment-experienced adults currently taking a standard of care (SOC) integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) regimen (Population 2). The study is designed to include the following phases: Randomized Intervention Phase (Step 1), Analytical Treatment Interruption (ATI) Phase (Step 2), and Follow-up Phase (Step 3).

03

Conditions studied

  • HIV Infections

Keywords

  • VH3810109
  • N6LS
  • Lotivibart (LVB)
  • Broadly neutralizing antibody (bNAb)
  • Fostemsavir (FTR)
  • RUKOBIA
  • INSTI-based ART
  • Human Immunodeficiency Virus (HIV)
  • HIV reservoir
  • Adults living with HIV
  • Analytical Treatment Interruption (ATI)
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

AGE

  • Age between 18 years and 70 years old at the time of obtaining .

SEX AND GENDER • Persons of any sex or gender are eligible. Note: Participants of (POCBP) are eligible to participate if not pregnant, not lactating, and agreeing to adhere to study requirements for use of and pregnancy avoidance.

PARTICIPANT KEY CHARACTERISTICS • Participant has a documented diagnosis of -1 infection. Note: Participants in Population 1 must have a documented positive HIV antibody result available for Screening.

Population 1 only:

  • Plasma HIV-1 RNA >=2000 copies/milliliter (c/mL) at Screening.
  • >=300 cells/microliter (μL) at Screening.
  • Antiretroviral treatment naïve, defined as no exposure to ART after a diagnosis of HIV-1 infection, prior to enrollment.

Population 2 only:

  • Participant is stably virologically suppressed (plasma HIV-1 RNA \<50 c/mL).
  • Documented evidence of uninterrupted treatment with oral non-boosted INSTI-based ART for at least 6 months prior to Screening, as well as uninterrupted treatment with ART (any guideline-recommended oral regimen) for at least 24 months prior to Screening.
  • CD4+ T cell count >=450 cells/μL at Screening.

WEIGHT

  • Body weight >=50 kg to \<=115 kg.

INFORMED CONSENT • Participant is capable of giving written informed consent, which includes adherence to the requirements and restrictions listed in the consent form and in the protocol.

Exclusion criteria

Exclusion Criteria:

CONCURRENT MEDICAL CONDITIONS \& MEDICAL HISTORY

  • Participant is pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study.
  • Participant has documented diagnosis of -2 infection.
  • Participant is known to have acquired HIV via perinatal transmission.
  • Any evidence of a current or known past Center for Disease Control and Prevention (CDC) Stage 3 disease.
  • Any ongoing or history of systemic cancers, such as Kaposi's sarcoma and lymphoma, or other virus-associated malignancies.
  • Ongoing or pancreatitis.
  • Current HIV-related kidney disease.
  • History of or active HIV-associated dementia or progressive multifocal leukoencephalopathy.

CARDIAC \& CARDIOVASCULAR CONDITIONS

  • Participants who are at clinically significant risk of cardiovascular disease.
  • Ongoing or any lifetime history of clinically significant cardiovascular or cardiac disease.
  • Confirmed value outside normal range at Screening or Day 1.

HEPATIC CONDITIONS

  • History of clinically relevant hepatitis in the 6 months prior to Screening.
  • Participants with severe hepatic impairment.
  • Advanced MAFLD and advanced non-alcoholic steatohepatitis, if evidence for substantial fibrosis (fibrosis score ≥F2) or evidence of cirrhosis.
  • Unstable liver disease.
  • History of liver cirrhosis with or without hepatitis viral co-infection.

NEUROPSYCHIATRIC CONDITIONS • Participants who pose a significant suicide risk.

LABORATORY DIAGNOSTIC ASSESSMENTS

  • Participants who are experiencing (Population 1) or are known to have initiated ART during (Population 2) acute HIV infection.
  • Any verified Grade 4 laboratory abnormality at Screening, excluding asymptomatic elevations of lipids or CPK.
  • Alanine transferase () >=3 times the (ULN) at Screening.
  • Estimated (eGFR) of \<60 mL/min/1.73 m\^2.
  • >=Grade 2 at Screening.
  • >=Grade 2 at Screening.
  • (ANC) ≥Grade 2 at Screening.
  • Any acute abnormality at Screening, which, in the opinion of the investigator, would preclude the participant's inclusion in an interventional clinical study.

Population 2 only:

  • Two or more plasma HIV-1 RNA results >=50 c/mL in the 18 months prior to Screening.

INFECTIOUS DISEASES

  • Active virus (HBV) co-infection.
  • Active virus (HCV) co-infection.
  • Participant has untreated syphilis before enrolment.
  • Known history of active Mycobacterium TB disease (regardless of treatment status).

ANTIRETROVIRAL RESISTANCE • Known major resistance-associated mutations to second-generation INSTIs or to antiretroviral (ARV) agents from 2 or more drug classes.

PRIOR AND CONCOMITANT MEDICATIONS

  • Prior use of any of the following agents:

    - long-acting ARVs (any dose in the past 24 months or within 5 half-lives [whichever is longer])

    - FTR (any lifetime use)

    - HIV-1 immunotherapeutic vaccines or prophylactic vaccines (any lifetime use)

    - HIV-1 monoclonal antibody therapy (any lifetime use).

  • Prior receipt of any approved or experimental non-HIV vaccination within 2 weeks prior to study enrolment.
  • History of systemic , anti-cancer, interleukins, systemic interferons, or systemic chemotherapy, within 6 months prior to Screening.
  • Participant has received an experimental drug or experimental vaccine within either 30 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent (whichever is longer), prior to enrolment.
  • Treatment with any of the following agents within 30 days of enrolment:

    - radiation therapy

    • cytotoxic chemotherapeutic agents
    • anti-tuberculosis therapy
    • immunomodulators that alter immune responses such as chronic systemic corticosteroids, interleukins, or interferons.
  • Participant is receiving any protocol-defined prohibited medication and is unwilling or unable to switch to an alternate medication. Prohibited medications must be stopped within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer), prior to enrolment.

Population 1 only:

  • Known use of PrEP or PEP within \<30 days (for oral agents) or \<52 weeks (for LA parenteral agents) of HIV-1 diagnosis. Participants with a documented seronegative result >=30 days after the last dose of oral PrEP or PEP (or >=52 weeks after the last dose of LA PrEP) are not excluded.

Population 2 only:

  • Current use of NNRTI-containing ART.

OTHER EXCLUSIONS

  • History or presence of allergy or intolerance to the study drugs or their components or drugs of their class, or a history of drug or other allergy that contraindicates study participation.
  • Any condition which may interfere with the absorption, distribution, metabolism or excretion of the study drugs or render the participant unable to receive study drugs.
  • Any pre-existing physical or mental condition (including substance use disorder) which, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.
  • Participant is currently participating in, or anticipates being selected for, any other interventional study.
  • Participant is known or suspected to be an HIV long-term non-progressor or elite controller, based on historical off-treatment plasma HIV-1 RNA results.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
107 participants (actual)

Study arms

  • Active comparator
    Participants receiving SOC INSTI-based ART in Randomized Intervention Phase (Step 1)

    Drug: SOC INSTI-based ART

  • Experimental
    Participants receiving SOC INSTI-based ART+VH3810109 in Randomized Intervention Phase (Step 1)

    Biological: VH3810109 · Drug: SOC INSTI-based ART

  • Experimental
    Participants receiving SOC INSTI-based ART+VH3810109+FTR in Randomized Intervention Phase (Step 1)

    Biological: VH3810109 · Drug: Fostemsavir (FTR) · Drug: SOC INSTI-based ART

  • Experimental
    Participants receiving VH3810109 in ATI Phase (Step 2)

    Biological: VH3810109

Interventions

  • BiologicalVH3810109

    VH3810109 will be administered.

    Also known as: Lotivibart (LVB)

  • Fostemsavir will be administered.

    Also known as: RUKOBIA

  • DrugSOC INSTI-based ART

    A SOC INSTI-based ART regimen will be administered.

06

What researchers measure

Primary outcomes

  1. Randomized Intervention Phase (Step 1): Change from baseline in cell-associated HIV-1 RNA transcripts per million cluster of differentiation 4 (CD4+) T cells

    Time frame: From Baseline (Day 1) to Month 12

Secondary outcomes

  1. Randomized Intervention Phase (Step 1): Change from baseline in total, intact, and defective proviral HIV-1 DNA per million CD4+ T cells

    Time frame: From Baseline (Day 1) to Month 12

  2. Randomized Intervention Phase (Step 1): Absolute change in cell-associated HIV-1 RNA/proviral DNA ratios in CD4+ T cells

    Time frame: From Baseline (Day 1) to Month 12

  3. Randomized Intervention Phase (Step 1): Absolute values for HIV-1-specific CD8+ T cell count

    Time frame: From Baseline (Day 1) to Month 12

  4. Randomized Intervention Phase (Step 1): Change from baseline in HIV-1-specific CD8+ T cell count

    Time frame: From Baseline (Day 1) to Month 12

  5. Randomized Intervention Phase (Step 1): Number of participants with Grade 3 and Grade 4 adverse events (AEs)

    Time frame: From Baseline (Day 1) to Month 15

  6. Randomized Intervention Phase (Step 1): Number of participants with serious adverse events (SAEs), deaths and AEs leading to discontinuation of study intervention

    Time frame: From Baseline (Day 1) to Month 15

  7. ATI Phase (Step 2): Time to ART restart

    Time frame: From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)

  8. ATI Phase (Step 2): Number of participants with Grade 3 and Grade 4 AEs

    Time frame: From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)

  9. ATI Phase (Step 2): Number of participants with SAEs and deaths

    Time frame: From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)

  10. ATI Phase (Step 2): Number of participants with disease progression (HIV-associated conditions, acquired immunodeficiency syndrome [AIDS] and death)

    Time frame: From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)

07

Study locations

41 sites
  • GSK Investigational Site
    Bakersfield, California 93309, United States
  • GSK Investigational Site
    San Diego, California 92103, United States
  • GSK Investigational Site
    Ft. Pierce, Florida 34982-7148, United States
  • GSK Investigational Site
    Orlando, Florida 32803-1851, United States
  • GSK Investigational Site
    Chicago, Illinois 60611, United States
  • GSK Investigational Site
    Kansas City, Missouri 64111, United States
  • GSK Investigational Site
    St Louis, Missouri 63110, United States
  • GSK Investigational Site
    New York, New York 10032, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45267, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15213, United States
  • GSK Investigational Site
    Dallas, Texas 75208-4599, United States
  • GSK Investigational Site
    Dallas, Texas 75246-2004, United States
  • GSK Investigational Site
    Ghent, Oost-Vlaanderen 9000, Belgium
  • GSK Investigational Site
    Brussels, 1000, Belgium
  • GSK Investigational Site
    Hvidovre, Capital Region 2650, Denmark
  • GSK Investigational Site
    Aarhus N, Central Jutland 8200, Denmark
  • GSK Investigational Site
    Rotterdam, 3015 GD, Netherlands
  • GSK Investigational Site
    Pozuelo de Alarcón, Madrid 28224, Spain
  • GSK Investigational Site
    Barcelona, 08003, Spain
  • GSK Investigational Site
    Barcelona, 08026, Spain
  • GSK Investigational Site
    Barcelona, 08035, Spain
  • GSK Investigational Site
    Barcelona, 08036, Spain
  • GSK Investigational Site
    Barcelona, 08916, Spain
  • GSK Investigational Site
    Barcelona, 8907, Spain
  • GSK Investigational Site
    Córdoba, 14004, Spain
  • GSK Investigational Site
    La Laguna Santa Cruz, 38320, Spain
  • GSK Investigational Site
    Madrid, 28020, Spain
  • GSK Investigational Site
    Madrid, 28031, Spain
  • GSK Investigational Site
    Madrid, 28034, Spain
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Madrid, 28046, Spain
  • GSK Investigational Site
    Palma de Mallorca, 07120, Spain
  • GSK Investigational Site
    Palma de Mallorca, 7198, Spain
  • GSK Investigational Site
    Seville, 41013, Spain
  • GSK Investigational Site
    Valencia, 46014, Spain
  • GSK Investigational Site
    Valencia, 46026, Spain
  • GSK Investigational Site
    London, NW3 2QG, United Kingdom
  • GSK Investigational Site
    London, SE1 7EH, United Kingdom
  • GSK Investigational Site
    London, W2 1NY, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.viiv-studyregister.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jan 2027, 18 months after the start.

Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's planned 18 months is above that.

Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2025
First posted
Jul 8, 2025
StartActual
Jul 10, 2025
Primary completionEst.
Jan 22, 2027
CompletionEst.
Sep 6, 2028
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 4 sites removed
Show 4 added (2 Denmark, 1 Belgium, 1 Spain)
  • GSK Investigational Site · Ghent, Belgium
  • GSK Investigational Site · Hvidovre, Denmark
  • GSK Investigational Site · Aarhus N, Denmark
  • GSK Investigational Site · Pozuelo de Alarcón, Spain
Show 4 removed
  • GSK Investigational Site · Ghent, Belgium
  • GSK Investigational Site · Aarhus, Denmark
  • GSK Investigational Site · Hvidovre, Denmark
  • GSK Investigational Site · Madrid, Spain
Sep 28, 2026
Enrollment
130 (estimated)→107 (actual)
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    4 sites added, 4 sites removed
    Show 4 added (2 Denmark, 1 Belgium, 1 Spain)
    • GSK Investigational Site · Ghent, Belgium
    • GSK Investigational Site · Hvidovre, Denmark
    • GSK Investigational Site · Aarhus N, Denmark
    • GSK Investigational Site · Pozuelo de Alarcón, Spain
    Show 4 removed
    • GSK Investigational Site · Ghent, Belgium
    • GSK Investigational Site · Aarhus, Denmark
    • GSK Investigational Site · Hvidovre, Denmark
    • GSK Investigational Site · Madrid, Spain
    Enrollment 130 (estimated)→107 (actual)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07053384
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Jul 8, 2025
Start date
Jul 10, 2025
Primary completion
Jan 22, 2027 (estimated)
Completion
Sep 6, 2028 (estimated)
Last update
Sep 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VH3810109

Start the discussion